Viewing Study NCT02896192

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:25 PM
Ignite Modification Date: 2026-06-14 @ 6:44 PM
Study NCT ID: NCT02896192
Status: COMPLETED
Last Update Posted: 2023-09-21
First Post: 2016-08-18
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
Sponsor: Rhythm Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pro-opiomelanocortin (POMC) Deficiency Obesity View
Keywords:

Keywords

Keyword Brief Keyword Text View
None POMC deficiency obesity View
None PCSK1 deficiency obesity View
None Setmelanotide View
None RM-493 View
None Obesity View
None Melanocortin 4 receptor View
None MC4R pathway View